PE109599A1 - Formas de dosificacion farmaceuticas solidas - Google Patents
Formas de dosificacion farmaceuticas solidasInfo
- Publication number
- PE109599A1 PE109599A1 PE1998000752A PE00075298A PE109599A1 PE 109599 A1 PE109599 A1 PE 109599A1 PE 1998000752 A PE1998000752 A PE 1998000752A PE 00075298 A PE00075298 A PE 00075298A PE 109599 A1 PE109599 A1 PE 109599A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical dosage
- dosage forms
- solid pharmaceutical
- soluble
- water
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5619597P | 1997-08-21 | 1997-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE109599A1 true PE109599A1 (es) | 1999-12-19 |
Family
ID=22002810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000752A PE109599A1 (es) | 1997-08-21 | 1998-08-20 | Formas de dosificacion farmaceuticas solidas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20010048946A1 (enExample) |
| EP (1) | EP1011640A1 (enExample) |
| JP (1) | JP2001515029A (enExample) |
| KR (1) | KR20010023085A (enExample) |
| AR (1) | AR018252A1 (enExample) |
| AU (1) | AU8600098A (enExample) |
| BR (1) | BR9811972A (enExample) |
| CA (1) | CA2292586C (enExample) |
| CO (1) | CO4960652A1 (enExample) |
| GT (1) | GT199800136A (enExample) |
| HN (1) | HN1998000115A (enExample) |
| NZ (1) | NZ502869A (enExample) |
| PA (1) | PA8458101A1 (enExample) |
| PE (1) | PE109599A1 (enExample) |
| SV (1) | SV1998000104A (enExample) |
| WO (1) | WO1999008660A1 (enExample) |
| ZA (1) | ZA987551B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69222847T3 (de) * | 1991-04-16 | 2005-09-15 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung einer festen dispersion |
| ES2096097T3 (es) * | 1991-08-02 | 1997-03-01 | Wilcom Tufting Pty Ltd | Procedimiento y sistema de formacion de nudos. |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
| CZ20022047A3 (cs) | 1999-12-23 | 2003-09-17 | Pfizer Products Inc. | Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| DE60143704D1 (de) * | 2000-09-25 | 2011-02-03 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer medizinischen festen dispersion |
| CA2363902C (en) * | 2000-12-07 | 2005-07-26 | Warner-Lambert Company | Process and system for controlled-release drug delivery |
| ES2333645T3 (es) | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
| GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
| GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
| ES2333318T3 (es) * | 2002-08-12 | 2010-02-19 | Bend Research, Inc. | Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero. |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| US20050100608A1 (en) * | 2003-02-21 | 2005-05-12 | Watson Pharmaceuticals, Inc. | Testosterone oral dosage formulations and associated methods |
| US8273371B2 (en) * | 2003-06-27 | 2012-09-25 | Johan Adriaan Martens | Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| GB0315012D0 (en) * | 2003-06-27 | 2003-07-30 | Leuven K U Res & Dev | Zeotiles |
| AR045062A1 (es) * | 2003-07-18 | 2005-10-12 | Santarus Inc | Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| BRPI0413277A (pt) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| RU2331410C2 (ru) * | 2003-12-04 | 2008-08-20 | Пфайзер Продактс Инк. | Способ получения фармацевтических мультичастиц |
| EP1718303A4 (en) * | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
| US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| EP1817008B1 (en) | 2004-11-09 | 2020-04-01 | Board of Regents, The University of Texas System | Stabilized hme composition with small drug particles |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| BRPI0519466B8 (pt) * | 2004-12-30 | 2021-05-25 | Pf Medicament | dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo |
| US20060147518A1 (en) * | 2004-12-30 | 2006-07-06 | Pierre Fabre Medicament | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
| FR2880274B1 (fr) * | 2004-12-30 | 2007-04-13 | Pierre Fabre Medicament Sa | Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication |
| BRPI0608609A2 (pt) * | 2005-05-10 | 2010-01-19 | Novartis Ag | processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis |
| GB0612695D0 (en) * | 2006-06-27 | 2006-08-09 | Univ Gent | Process for preparing a solid dosage form |
| AU2007335191A1 (en) * | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical compound and composition |
| CA2729596A1 (en) * | 2008-07-03 | 2010-01-07 | Novartis Ag | Melt granulation process |
| WO2010136604A1 (en) * | 2009-05-29 | 2010-12-02 | Dsm Ip Assets B.V. | Transfer matrix for transferring a bioactive agent to body tissue |
| KR20140006879A (ko) | 2011-02-17 | 2014-01-16 | 에프. 호프만-라 로슈 아게 | 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법 |
| PH12014500593A1 (en) * | 2011-09-14 | 2019-09-02 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6038322A (ja) * | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固形製剤 |
| JPH054919A (ja) * | 1990-07-25 | 1993-01-14 | Sankyo Co Ltd | チアゾリジン誘導体の固体分散体 |
| DE69222847T3 (de) * | 1991-04-16 | 2005-09-15 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung einer festen dispersion |
| ES2109377T3 (es) * | 1991-12-18 | 1998-01-16 | Warner Lambert Co | Proceso para la preparacion de una dispersion solida. |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| DE4226753A1 (de) * | 1992-08-13 | 1994-02-17 | Basf Ag | Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen |
| JPH07324086A (ja) * | 1994-05-31 | 1995-12-12 | Sankyo Co Ltd | チアゾリジン誘導体の固体分散体または固体分散体製剤 |
| DE19515972A1 (de) * | 1995-05-02 | 1996-11-07 | Bayer Ag | Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung |
-
1998
- 1998-07-24 HN HN1998000115A patent/HN1998000115A/es unknown
- 1998-07-29 WO PCT/US1998/015693 patent/WO1999008660A1/en not_active Ceased
- 1998-07-29 JP JP2000509400A patent/JP2001515029A/ja not_active Abandoned
- 1998-07-29 EP EP98937241A patent/EP1011640A1/en not_active Withdrawn
- 1998-07-29 AU AU86000/98A patent/AU8600098A/en not_active Abandoned
- 1998-07-29 US US09/284,858 patent/US20010048946A1/en not_active Abandoned
- 1998-07-29 BR BR9811972-9A patent/BR9811972A/pt not_active Application Discontinuation
- 1998-07-29 NZ NZ502869A patent/NZ502869A/xx unknown
- 1998-07-29 CA CA002292586A patent/CA2292586C/en not_active Expired - Fee Related
- 1998-07-29 KR KR1020007001704A patent/KR20010023085A/ko not_active Ceased
- 1998-08-19 AR ARP980104098A patent/AR018252A1/es unknown
- 1998-08-20 PA PA19988458101A patent/PA8458101A1/es unknown
- 1998-08-20 GT GT199800136A patent/GT199800136A/es unknown
- 1998-08-20 ZA ZA987551A patent/ZA987551B/xx unknown
- 1998-08-20 CO CO98047585A patent/CO4960652A1/es unknown
- 1998-08-20 PE PE1998000752A patent/PE109599A1/es not_active Application Discontinuation
- 1998-08-20 SV SV1998000104A patent/SV1998000104A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SV1998000104A (es) | 1999-07-02 |
| US20010048946A1 (en) | 2001-12-06 |
| AR018252A1 (es) | 2001-11-14 |
| EP1011640A1 (en) | 2000-06-28 |
| JP2001515029A (ja) | 2001-09-18 |
| HN1998000115A (es) | 1999-06-02 |
| CA2292586C (en) | 2006-02-14 |
| GT199800136A (es) | 2000-02-11 |
| CA2292586A1 (en) | 1999-02-25 |
| NZ502869A (en) | 2002-10-25 |
| AU8600098A (en) | 1999-03-08 |
| BR9811972A (pt) | 2000-08-15 |
| ZA987551B (en) | 1999-02-23 |
| PA8458101A1 (es) | 2001-12-14 |
| CO4960652A1 (es) | 2000-09-25 |
| KR20010023085A (ko) | 2001-03-26 |
| WO1999008660A1 (en) | 1999-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE109599A1 (es) | Formas de dosificacion farmaceuticas solidas | |
| UY26496A1 (es) | Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco | |
| CU23440B7 (es) | Composición de liberación sostenida de pramipexol | |
| AR046811A1 (es) | Formas de dosificacion oral de ziprasidona de liberacion sostenida | |
| ATE253894T1 (de) | Pharmazeutische suspensionssysteme | |
| ATE251449T1 (de) | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe | |
| ATE381926T2 (de) | Vitaminzusammenstellung mit verzögerter freigabe | |
| JP2001515029A5 (enExample) | ||
| ATE372765T1 (de) | Feste pharmazeutische formulierungen mit telmisartan | |
| UY28281A1 (es) | Productos farmacéuticos | |
| DE69735002D1 (de) | Osmotisches Verabreichungssystem für lösliche Dosen | |
| WO2004110492A3 (en) | Composition comprising triptans and nsaids | |
| DE69928815D1 (de) | Dosierungsform mit flüssiger formulierung | |
| DE69923336D1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
| ES2130081B1 (es) | Comprimido de maleato de trimebutina con recubrimiento laminar. | |
| EP1221926A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH POOR SOLVENT MEDICAMENTS | |
| DE69927374T2 (de) | Entzündungshemmende pharmazeutische formulierungen | |
| ECSP034451A (es) | Composicion de eletriptan en forma de particulas | |
| CO5200833A1 (es) | Regimenes de dosificacion para lasofoxifeno | |
| UY28461A1 (es) | Composición nueva | |
| ES2040891T3 (es) | Nuevo sistema plastificante hidrofilo y goma de mascar que contiene el mismo. | |
| CR8948A (es) | Composicion farmaceutica | |
| CR8973A (es) | Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua | |
| SE9902742D0 (sv) | New pharmaceutical formultion | |
| ECSP034463A (es) | Composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |